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Purpose: Associations of radiation therapy (RT) deviations and outcomes in medulloblas-
toma have not been deﬁned well, particularly in the era of reduced-dose craniospinal
irradiation and chemotherapy. The aim of this study is to evaluate the quality of RT
on Children’s Cancer Group/Pediatric Oncology Group 9961 and analyze associations of
RT deviations with outcome. Materials and Methods: Major volume deviations were
assessed based on the distance from speciﬁed anatomical region to ﬁeld edge.We inves-
tigated associations of RT deviations with progression-free survival (PFS), overall survival
(OS), and explored associations with demographics and clinical variables. Results: Of the
308 patients who were evaluable for volume deviations, 101 patients (33%) did not have
any. Of the remaining 207 patients, 50% had only minor deviations, 29% had only major
deviations, and 21% had both minor and major deviations. Of the patients with major devi-
ations, 73% had a single major deviation. The most common major deviation was in the
cribriform plate region, followed by the posterior fossa (PF); PF deviations resulted from
treating less than whole PF. There were no signiﬁcant differences in PFS or OS between
patients with deviations and thosewithout.There was no evidence of associations of devia-
tions with patient age. Conclusions:Approximately one-third of patients hadmajor volume
deviations.Therewas no evidence of a signiﬁcant association between these and outcome.
This lack of correlation likely reﬂects the current high quality of RT delivered in Children’s
Oncology Group institutions, our strict deﬁnition of volume deviations, and the relatively
few instances of multiple major deviations in individual patients. In is noteworthy that the
types of PF volume deviations observed in this study were not adversely associated with
outcome. As we move forward, quality assurance will continue to play an important role
to ensure that deviations on study do not inﬂuence study outcome.
Keywords: medulloblastoma, radiation therapy, quality assurance, craniospinal, posterior fossa
INTRODUCTION
Craniospinal irradiation (CSI) provides the backbone for the
deﬁnitive treatment of medulloblastoma (MB). Its planning and
delivery is considered one of the most technically challenging of
radiation treatments. It is generally accepted that quality con-
trol of CSI, with strict adherence to protocol guidelines, is an
essential part of the appropriate treatment of MB. However,
associations of radiation therapy (RT) deviations and outcome
have not been deﬁned clearly, particularly in the modern era of
reduced-dose CSI and chemotherapy. The aim of this study was
to investigate associations of the quality of RT and the outcome
of children with posterior fossa (PF) MB treated prospectively on
Children’s Cancer Group/Pediatric Oncology Group (CCG/POG)
9961 with reduced-dose CSI and chemotherapy. We describe the
types of deviations identiﬁed, the association of RT deviations
with progression-free survival (PFS) and overall survival (OS),
and explore relationships between clinical variables, deviations,
and outcome.
MATERIALS AND METHODS
Children’s Cancer Group/Pediatric Oncology Group 9961 was a
phase III trial designed for childrenwith standard riskMB (deﬁned
as no evidence of disseminated disease on magnetic resonance
imaging of the entire brain and spine or on cytologic exami-
nation of lumbar CSF, and less than 1.5 cm2 of residual tumor
on postoperative neuroimaging) to determine if postradiotherapy
cyclophosphamide would increase the rate of PFS as compared
with aCCNU-containing regimen, and todetermine the event-free
survival (EFS),OS, and patterns of relapse with reduced-dose CSI.
A dose of 23.4 Gy was to be delivered to the craniospinal axis with
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photons (electrons for the spinal ﬁeld were allowed) in 1.8 Gy daily
fractions with a boost to the entire PF of 32.4 Gy in 18 fractions for
a total dose of 55.8 Gy in 31 fractions. Dose homogeneity of +7
and −5% relative to the prescription point was required through-
out the central plane of the brain and PF ﬁelds, and along the
longitudinal axis of the spinal cord; inhomogeneity correction for
bonewas not allowed. RTwas to startwithin 31 days of surgery and
be completed within 51 days of the start of RT. Details regarding
the speciﬁcs of the chemotherapy delivery have previously been
described (Packer et al., 2006).
Guidelines for the treatment volumes were outlined in the pro-
tocol. The cranial volume was to extend anteriorly to cover the
entire frontal lobe and cribriform plate region, thus including
the superior orbital tissue. The inferior border was to be at least
5 mm below the base of skull and matched to the superior bor-
der of the spinal ﬁeld. A single posterior spinal ﬁeld extending
laterally to cover the recesses of the entire vertebral bodies with
at least a 1-cm margin on either side (with extended source-to-
skin distance if necessary) was preferred over adjacent spine ﬁelds;
superiorly it extended to the caudad border of the cranial ﬁeld uti-
lizing appropriate matching technique. Inferiorly, the ﬁeld was to
extend 1–2 cm below the termination of the thecal sac as identiﬁed
on sagittal MRI; a “spade” was to be used as needed to cover the
nerve roots exiting the neural foramen. A 5-mm skin gap between
the cranial and spinal ﬁelds was allowed, and this junction was to
be moved at least twice during CSI. The boost volume included
the entire PF with a 1-cm margin. Use of sagittal MRI to shape
the superior border 1 cm above tentorium was encouraged. The
anterior margin extended to the posterior clinoids (with shield-
ing of the pituitary), and inferiorly the ﬁeld extended to the C1/2
junction with the anterior border in that location being placed at
the anterior edge of the vertebral bodies. The PF boost generally
was delivered with lateral parallel-opposed portals; however, 3D
planned boosts to the entire PFwere allowed. Rapid central review,
deﬁned as review of the simulation ﬁlms and portal images within
3 days of the institution of RT at Quality Assurance Review Center
(QARC), was mandated for patients enrolled through POG; this
was optional for patient enrolled through the CCG.
A retrospective analysis of the RT data was undertaken. All
submitted simulation and portal images were reviewed and
assessed for appropriateness of covered volumes utilizing guide-
lines adapted from, but not identical to, those published by
Miralbell et al. (2006). Cranial simulation and portal ﬁlms were
evaluated for adequate coverage of the meninges. The cribriform
plate andmiddle cranial fossa were scored separately. The distance
between each of these regions and the inferior border (generally
deﬁned by a block) was measured. Amajor deviation was scored if
the distance from the speciﬁed anatomical region to the block edge
was 0 mm or if the block impinged upon the speciﬁed anatom-
ical region; if the distance was 1–4 mm, a minor deviation was
scored.
Coverage on the spinal axis was assessed by measuring the dis-
tance from the lateral recess to the ﬁeld edge laterally and by the
distance from the inferior edge of the thecal sac to the inferior edge
of the spine ﬁeld. PF volumes were assessed based on the place-
ment of the anterior border at the posterior clinoid, the distance
of the superior ﬁeld edge from the tentorium, the distance of the
posterior/inferior margin from the skull, and inferiorly from the
C1/2 interspace. For both the spinal axis and the PF a major devi-
ation was scored if the ﬁeld edge or block abutted or transected
the speciﬁed anatomical region; a minor deviation was scored if
this distance was 1–5 mm. Dose and isodose distributions were
not reviewed as part of this analysis, as initial central review of
these revealed few deviations. The diagnostic ﬁlms of patients who
relapsed were reviewed in conjunction with the treatment portals
to determine the location of the relapse with respect to the RT
ﬁelds. The time interval from deﬁnitive surgery to start of RT was
also analyzed for its inﬂuence on outcome.
STATISTICS
Progression-free survival was deﬁned as the time from on-study
date to the earliest date of relapse, secondarymalignancy, or death.
OSwas deﬁned as the time fromon-study date to the date of death.
Patientswhodidnot experience an event (death) forPFS (OS)were
censored at their last follow-up date. PFS and OS distributions
were estimated using the Kaplan–Meier method and compared
among sub-populations of patients using a log-rank test. In esti-
mating cumulative incidence of local relapse, competing events
were considered to be distant relapse, secondary malignant neo-
plasms, and death; similarly, in estimating cumulative incidence
of distant relapse, competing events were local relapse, secondary
malignant neoplasms, and death.
RESULTS
Four hundred twenty-one patients were enrolled on CCG/POG
9961 between 1994 and 2000. Forty-two patients were excluded
from analysis for the following reasons: thirty with high-risk dis-
ease on central review, four with ineligible pathology, four with
incomplete staging, one with an excessive delay in treatment, one
with inadequate informed consent, and two without follow-up.
Of the 379 remaining patients, 66 had poor quality or incomplete
submission of neuroimaging and could not be fully evaluated on
central review, and RT deviations could not be determined for ﬁve
other patients; thus, 308were evaluable for volumedeviations. The
vast majority of patients were simulated with 2D techniques uti-
lizing photons. Eight patients were treated with protons; electrons
were rarely used for treatment of spinal ﬁelds.
There were 146 major deviations which occurred in 104
patients. 101 patients (33%) did not have any RT deviations.
Of the remaining 207 patients, 103 had only minor deviations,
60 had only major deviations, and the remaining 44 had both
minor andmajor deviations (seeTable 1). RT deviationswere sim-
ilarly distributed in both study arms. For 308 evaluable patients,
one major deviation was identiﬁed in 76 (24.7%) patients, two
major deviations in 18 (5.8%), and three major deviations in
7 (2.3%).
TYPES OF VOLUME DEVIATION
The major deviations were categorized by anatomical site (see
Table 2). The most common major deviation was related to the
cribriform plate region. The next site to most frequently incur a
deviation was the PF. Major deviations along the middle cranial
fossa occurred in almost equal frequency to major deviations of
the PF. Major deviations in the spinal ﬁelds were uncommon, as
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Table 1 | Summary of deviations for the 308 evaluable patients.
Type of deviation Number of patients (%)
None 101 (32.8)
Major only 60 (19.5)
Minor only 103 (33.4)
Both 44 (14.3)
Total 308 (100)
Table 2 |Types of major deviations for the 308 evaluable patients.
Location Number of patients (%)
Cribriform plate 79 (25.6)
Middle cranial fossa 25 (8.1)
Spine 3 (1)
Posterior fossa 27 (8.8)
Other* 12 (3.9)
*Includes anterior border of cervical spine, skull perimeter/occiput, anterior
cranial fossa.
were other sites along the base or perimeter of the skull and the
anterior upper cervical spine.
ASSOCIATION OF DEVIATIONS WITH SURVIVAL
There was no association of deviations with either PFS (p = 0.084)
or OS (p = 0.36; see Figures 1 and 2), although patients with both
minor and major deviations appear to have more favorable PFS
(p = 0.022). Furthermore, the number of deviations (analyzed
as 0, 1–2, and ≥3) did not correlate with outcome (Figures 3
and 4); when the number of major deviations alone was ana-
lyzed, there was also no difference in PFS or OS. Seventy-one
of the 379 eligible protocol patients did not have data available
to assess for RT deviations. There was no selection bias, as evi-
denced by no statistical difference in PFS or OS between these
inevaluable patients and the 308 patients for whom this data was
available.
POSTERIOR FOSSA DEVIATIONS
We also evaluated whether the site of the deviation inﬂuenced
outcome. There was no statistically signiﬁcant association of devi-
ations at the cribriform plate or middle cranial fossa with PFS or
OS. Interestingly, however, there was a suggestion of better PFS in
patients with PF deviations when major and minor deviations in
this site were combined (p = 0.013; see Figure 5), and a suggestion
of a lower incidence of relapse (p = 0.025; see Figure 6); there was
no association with OS (Figure 7).
The most common PF deviation resulted primarily from treat-
ing less than the whole PF. In approximately half of these, the
volume did not extend to the posterior clinoid. In the remaining
cases, the ﬁeld borders did not extend superiorly or posteriorly
enough to allow for adequate coverage of the entire PF. In no case
was the tumor bed or gross tumor shielded.
ASSOCIATION OF CLINICAL VARIABLES AND DEVIATIONS
We evaluated the association of age on the presence and types of
deviations. There was no statistically signiﬁcant association of age
with the number of eithermajor orminor deviations. Additionally,
we evaluated whether age was associated with RT deviations of the
cribriform plate. There was no clear correlation between age and
the incidence of deviations on the cribriform plate.
We investigated the association of the time elapsed from surgery
to the initiation of RT with the occurrence of RT deviations. The
protocol speciﬁed interval from surgery to the start of RT was 31
days. Of the 308 eligible patients, 284 (92.2%) patients started
within the protocol speciﬁed interval. The median time between
deﬁnitive surgery and the start of RT was 27 days (range 4–46
days), and only ﬁve patients started within a 14-day interval. The
interval from surgery to the start of RT was not different between
patients with RT deviation vs. patients without (Wilcoxon–
Mann–Whitney test p-values were 0.18, 0.091, and 0.051, respec-
tively for major, minor, and combined major and minor RT
deviations).
DISCUSSION
Medulloblastoma disseminates along craniospinal ﬂuid pathways,
and adequate coverage of the cranial and spinal contents is con-
sidered mandatory for the successful eradication of disease. To
our knowledge, this is the largest review to date of the technical
factors related to RT for the treatment of PF MB. The association
between radiation treatment technique and patterns of failures
and/or relapse rates has been explored by several authors over
the past 30 years. Miralbell et al. (1997) reported a review of
the whole brain RT portals in 77 patients, and in nearly half the
patients, the inferior portions of the frontal and temporal lobes
were judged to be “missed.” Of the 12 patients who failed in the
supratentorial region, nine belonged to the group in whom the
inferior portion of the brain had been underdosed. Correlation
between “correct placement” of the brain ﬁeld and supratentorial
failure-free survival was observed.
Carrie et al. (1999) reported the impact of targeting deviations
on outcome in the French Society of Pediatric Oncology (SFOP)
experience with both standard risk and high-risk MB. The most
frequent major deviation identiﬁed in the 169 patients evaluable
for correlation between targeting deviation and the site of relapse
was the cribriform plate and the lower part of the temporal lobe.
Seventy percent of patients had at least one minor or major devi-
ation, and 31% of patients had at least one major deviation. The
number of major deviations in RT was correlated with the risk
of tumor relapse: 67% 3-year relapse rate in patients with two
deviations and 78% in patients with three major deviations. The
incidence of major deviations reported in this study is similar to
ours, however, comparison of the ﬁndings from the SFOP experi-
encewith our data is confoundedby inclusion of high-risk cohorts,
the use of neoadjuvant chemotherapy, and the start of RT at day 90
in SFOP. It is possible that in the setting of delayed RT,“marginal”
misses havemore of impact on outcome thanwhen RT is delivered
immediately following surgery.
In a quality assessment review of 167 patients with high-risk
MB treated on POG 9031, 26% had major deviations in the brain
ﬁelds, 7% in the spine, and 40% in the PF (Miralbell et al., 2006).
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FIGURE 1 | Association of RT deviations and progression-free survival.
FIGURE 2 | Association of RT deviations and overall survival.
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FIGURE 3 | Association of number of deviations and progression-free survival.
FIGURE 4 | Association of number of deviations and overall survival.
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FIGURE 5 | Association of posterior fossa deviations and progression-free survival.
FIGURE 6 | Cumulative incidence of local and distant relapse by
posterior fossa deviations.
Forty percent of patients had “inaccuracies” equivalent to our
“minor deviations” in the region of the frontal lobe, and 20%
in the middle cranial fossa. Including dose, more than half the
evaluable patients had a major deviation, and these were not asso-
ciated with a worse survival. However, of interest, patients with
zero to one major deviation as compared to those with two to four
major deviations, had a 5-year EFS of 71.0 vs. 61.8% (p = 0.30),
and 5-year OS was 76.6 vs. 69.9% (p = 0.22), respectively.
Until recently, delivery of doses on the order of 54–55.8 Gy to
the entire PF has been felt to be a necessary component for the suc-
cessful irradiationofMB.ThePOG9031RTquality review showed
that 40% of patients had major deviations in the PF, however,
there was no correlation between deviations and survival (Miral-
bell et al., 2006). Several reports from single institutions in which
less-than-whole PF boosts have been utilized have shown 5-year
PFS on the order of 80% with rare isolated PF failures outside
the involved ﬁeld boost (Fukunaga-Johnson et al., 1998; Merchant
et al., 2008; Carrie et al., 2009; Polkinghorn et al., 2011). The type
of PF volume deviations which occurred in nearly 10% of patients
on our study did not correlate with outcome. Our ﬁndings lend
credence to the idea that treatment of the tumor bed and amargin
to full dose, rather than the entire PF,may be sufﬁcient, and add to
the justiﬁcation to study involved ﬁeld vs. a PF ﬁeld in the setting
of combined modality therapy for standard risk MB.
It is important to emphasize that our ﬁndings should not be
interpreted as lessening the value of precisely placed ﬁelds. Our
study is limited by the 2D nature of the data, and the lack of cor-
relation of deviations and outcome likely reﬂects both the current
high quality of RT delivered in Children’s Oncology Group (COG)
institutions as well as our strict deﬁnition of volume deviations.
The lack of correlation between deviations and outcome could be
the result of other factors, such as type II error; however, for crib-
riform plate deviations, the sample size was adequate to detect a
reasonable difference between the PFS distributions (79 patients
with major RT deviation, 83 patients with minor RT deviations),
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FIGURE 7 | Association of posterior fossa deviations and overall survival.
and therefore, for cribriform plate deviations, we cannot invoke
type II error as an explanation for the lack of correlation. However,
for deviations associated with the middle cranial fossa, the sample
size was limited (25 patients with major RT deviations, 34 patients
with minor RT deviations) and we may not have sufﬁcient power
to detect an existing difference. The direction of a possible differ-
ence in PFS for these deviations (middle cranial fossa) is similar to
patientswithPFdeviations, i.e., patientswithminorormajor devi-
ations seem to have better PFS and OS overall, but the difference
did not reach statistical signiﬁcance.
The SFOP and POG experiences suggest that radiation treat-
ment execution does impact patient outcome. Treatment set up
for this disease is challenging as a 5-mm shift in patient align-
ment can bring the radiation ﬁeld edge into the intended target
of both the central nervous system and the spine. Carrie et al.
(1999) and Miralbell et al. (2006) have demonstrated that often
multiple deviations must be present in the same patient in order
to inﬂuence outcome. Deviations on our study were assigned at
several anatomical locations, perhaps making it more difﬁcult to
demonstrate that individual deviations directly affect outcome.
Furthermore, nearly three-quarters of the patients on our study
who had major deviations had only one major deviation, thus
potentially limiting our ability to detect an effect.
The issuemoving forward is to put a strategy in place to limit or
eliminate deviations on study, such that there is no question that
these deviations could inﬂuence study outcome. We are entering
a phase where biomarkers and targeted therapies will be incorpo-
rated into the next generation of MB studies, therefore limiting
RT deviations will be important to validate new therapies moving
forward. There is evidence that quality assurance in clinical trials
involving RT may be inﬂuenced by RT quality even when RT is
not the trial objective (Peters et al., 2010), therefore limiting RT
deviations on study moving forward will be important in the next
generation of clinical trials for MB.
In situations where there have been excessive deviations on
study, the RT committee of the COG has moved to pre-treatment
central review of treatment objects in order to limit deviations on
study. With the expansion of digital transfer of both images and
RT treatment objects, real time review of objects including inter-
national sites of participation is both feasible and reasonable to
achieve. There are differences in deﬁning the meningeal surface
including the cribriform plate, anterior temporal lobe, and the
base of the skull. These areas are also age driven in target deﬁni-
tion, especially the cribriform region which lies at the parallax of
the lens until the age of 9. Our criteria for cribriform plate devi-
ations included not just transection of this area by a block, but
abutment of the ﬁeld edge to this region. Despite an increasing
appreciation of the location of the cribriformplate with the advent
of CT planning, this area remains at risk for being blocked, and
this may reﬂect the bias of the treating physicians who wish to
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spare the lens. The frontal sinuses develop during the ﬁrst and sec-
ond year of life and move to their ﬁnal position above the orbital
ridge by 5 or 6 years of age, however, the frontal sinuses are not
completely developed until late adolescence. Thus, in young chil-
dren in whom the cribriform plate is anatomically closer to the
lens, it becomes almost impossible to shield the lens and deliver
“appropriate” dose to the cribriform.
Differences in interpretation of anatomical landmarks often
contribute to study deviations. Developing age-related atlases
for the meningeal surface and ﬁnal phase recommendations can
be very helpful and lead to successful execution of the clinical
trial. Data at QARC suggests that once an atlas is developed,
study deviations decrease. Coupled with real time interventional
review of objects, these tools may be very helpful in limit-
ing deviations in MB clinical trials. MB clinical trials require
signiﬁcant participation in both the national and international
treatment community to meet accrual objectives. As we move for-
ward with the next generation of MB studies, subsets for study
in this disease will be established based on molecular pheno-
type, and quality assurance will continue to play an important
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